title: The role of progestin receptors and the mitogen-activated protein kinase pathway in delta opioid receptor facilitation of female reproductive behaviors.
abstract: The present study investigated the role of the progestin receptor (PR) and the mitogen-activated protein kinase (MAPK) pathway in the facilitation of lordosis behavior by the delta opioid receptor agonist [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE). Ovariectomized, estrogen-primed rats were treated with the PR antagonist RU486 or the MAPK inhibitor PD98059 prior to intraventricular (icv) infusion of DPDPE. Both RU486 and PD98059 blocked receptive and proceptive behaviors induced by DPDPE at 60 min, and RU486 continued to inhibit estrous behavior at 90 min. Because delta opioid receptors can activate the p42/44 MAPKs, extracellular signal regulated kinases (ERK), we determined the effects of DPDPE on ERK phosphorylation. Icv infusion of DPDPE increased the levels of phosphorylated ERK in the hypothalamus and preoptic area of female rats, assessed by immunoblotting. These results support the participation of the PR and the MAPK pathway in the facilitation of lordosis behavior by delta opioid receptors.
authors.affiliation: Department of Neuroscience F113, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
authors.forename: Maricedes
authors.initials: M
authors.lastname: Acosta-Martínez
authors.forename: Oscar
authors.initials: O
authors.lastname: Gonzalez-Flores
authors.forename: Anne M
authors.initials: AM
authors.lastname: Etgen
mesh_terms: D000818:Animals; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage; D006727:Hormone Antagonists / Q000008:administration & dosage; D007276:Injections, Intraventricular; D008297:Male; D015735:Mifepristone / Q000008:administration & dosage; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000008:administration & dosage; D010766:Phosphorylation; D011187:Posture / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000187:drug effects / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*
chemical_list: D004791:Enzyme Inhibitors; D005419:Flavonoids; D006727:Hormone Antagonists; D018377:Neurotransmitter Agents; D017465:Receptors, Opioid, delta; D011980:Receptors, Progesterone; D015735:Mifepristone; D020881:Enkephalin, D-Penicillamine (2,5)-; D020928:Mitogen-Activated Protein Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one